Centessa Pharmaceuticals PLC Form 4 insider transactions

Centessa Pharmaceuticals' Chief Technology & Quality Officer, Tia L. Bush, exercised stock options and subsequently sold an equal number of shares under a pre-arranged trading plan.

Centessa Pharmaceuticals' Chief Technology & Quality Officer, Tia L. Bush, exercised stock options and subsequently sold an equal number of shares for a significant gain.

Centessa Pharmaceuticals plc's President of Orexin Program, Mario Alberto Accardi, reported a sale of 593 ordinary shares to cover tax obligations.

Centessa Pharmaceuticals plc officer Mario Alberto Accardi exercised stock options and subsequently sold a portion of his shares under a pre-arranged 10b5-1 trading plan.

Centessa Pharmaceuticals General Counsel Iqbal J Hussain exercised stock options and subsequently sold a portion of his shares under a pre-arranged trading plan.

Centessa Pharmaceuticals' Chief Technology & Quality Officer, Tia L. Bush, exercised options and sold 35,000 ordinary shares for a profit.

Centessa Pharmaceuticals plc President, Orexin Program, Mario Alberto Accardi, sold 8,172 ordinary shares on September 16, 2025, under a pre-arranged 10b5-1 trading plan.

Centessa Pharmaceuticals General Counsel Iqbal J Hussain exercised stock options and subsequently sold 6,000 ordinary shares for a profit under a pre-arranged trading plan.

Centessa Pharmaceuticals' Chief Technology & Quality Officer, Tia L. Bush, exercised stock options and subsequently sold shares totaling 49,792 ordinary shares over two days.

Centessa Pharmaceuticals' General Counsel, Iqbal J. Hussain, sold 40,000 ordinary shares in two transactions after exercising options, pursuant to a pre-arranged 10b5-1 trading plan.

Centessa Pharmaceuticals' President of Orexin Program, Mario Alberto Accardi, sold 7,000 ordinary shares after exercising options, pursuant to a pre-arranged 10b5-1 trading plan.

Centessa Pharmaceuticals plc's General Counsel, Iqbal J Hussain, exercised stock options and sold an equivalent number of shares under a pre-arranged trading plan.

Centessa Pharmaceuticals plc's President of Orexin Program, Mario Alberto Accardi, disposed of 597 ordinary shares to cover tax withholding obligations related to restricted share unit vesting.

Centessa Pharmaceuticals plc's President of Orexin Program, Mario Alberto Accardi, sold 8,322 ordinary shares for approximately $15.23 per share, executed under a Rule 10b5-1 trading plan.

Centessa Pharmaceuticals plc's Chief Business Officer, Gregory M. Weinhoff, exercised stock options and simultaneously sold a portion of the resulting shares on July 25, 2025, under a Rule 10b5-1 trading plan.

Centessa Pharmaceuticals plc CEO Saurabh Saha exercised stock options and sold an equivalent number of shares on July 21, 2025, under a pre-established Rule 10b5-1 trading plan.

Centessa Pharmaceuticals plc's General Counsel, Iqbal J. Hussain, exercised stock options and subsequently sold 6,000 ordinary shares for a profit, as part of a pre-arranged Rule 10b5-1 trading plan.

Centessa Pharmaceuticals plc's Chief Business Officer, Gregory M. Weinhoff, exercised stock options and subsequently sold a portion of his shares on June 25, 2025, as part of a Rule 10b5-1 trading plan.

Centessa Pharmaceuticals plc's General Counsel, Iqbal J. Hussain, exercised stock options and subsequently sold a portion of the acquired shares on June 24, 2025, as part of a pre-established Rule 10b5-1 trading plan.

Centessa Pharmaceuticals plc's President of Orexin Program, Mario Alberto Accardi, executed a pre-planned transaction, exercising stock options and simultaneously selling 15,000 ordinary shares for a significant profit.

Centessa Pharmaceuticals plc director Arjun Goyal was granted 40,000 stock options with an exercise price of $12.43 per share, aligning his interests with shareholder value.

Centessa Pharmaceuticals plc director Mary Lynne Hedley was granted 40,000 stock options with an exercise price of $12.43, vesting based on continued service.

Centessa Pharmaceuticals plc Director Mathias Hukkelhoven was granted 40,000 share options with an exercise price of $12.43, vesting over one year or until the next annual meeting, as disclosed in a recent SEC Form 4 filing.

Centessa Pharmaceuticals plc Director Samarth Kulkarni has been granted 40,000 share options with an exercise price of $12.43, aligning his interests with shareholder value.

Centessa Pharmaceuticals plc Director Carol Stuckley has been granted 40,000 share options with an exercise price of $12.43, aligning her interests with long-term shareholder value.

Centessa Pharmaceuticals plc director Brett I. W. Zbar was granted 40,000 share options with an exercise price of $12.43, vesting on the earlier of one year from grant or the next annual meeting.

Centessa Pharmaceuticals plc CEO Saurabh Saha exercised stock options and subsequently sold 55,000 ordinary shares for approximately $12.63 per share, as part of a pre-established 10b5-1 trading plan.

Centessa Pharmaceuticals plc's Chief Accounting Officer, Raphael Deferiere, was granted 165,000 share options with an exercise price of $13.41, vesting over a multi-year period.

Centessa Pharmaceuticals' Chief Business Officer, Gregory M. Weinhoff, exercised stock options and subsequently sold 10,000 ordinary shares for a significant gain, as disclosed in a recent SEC Form 4 filing.

CEO Saurabh Saha exercised options and sold 55,000 ordinary shares of Centessa Pharmaceuticals under a pre-arranged Rule 10b5-1 trading plan.